Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KAT6A | Q92794 | 9/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287138 | 0.92 | GFER (0.52) | HTTKAT6AGFERGAAALDH1A1 | |
| SCHEMBL660454 | 0.90 | KAT6A (0.51) | KAT6AGAAALDH1A1MAPTMEN1 | |
| SCHEMBL658510 | 0.89 | POLB (0.47) | HTTKAT6AGFERGAAALDH1A1 | |
| SCHEMBL658335 | 0.85 | ALDH1A1 (0.61) | HTTKAT6AGFERGAAALDH1A1 | |
| SCHEMBL297855 | 0.85 | ALDH1A1 (0.42) | HTTGFERGAAALDH1A1MAPT | |
| SCHEMBL660526 | 0.83 | KAT6A (0.35) | KAT6AGAAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL298474 | 0.80 | SMN1; SMN2 (0.40) | GAAALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL27592073 | 0.79 | HTT (0.53) | HTTKAT6AGFERGAAALDH1A1 | |
| SCHEMBL658334 | 0.79 | GAA (0.43) | KAT6AGAAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7805087 | 0.78 | HDAC1 (0.40) | GAAALDH1A1MAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | claimed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | HTT 75/4885KAT6A 1650/4885GFER 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.